155 related articles for article (PubMed ID: 30942459)
1. Pharmacological inhibition of EZH2 combined with DNA‑damaging agents interferes with the DNA damage response in MM cells.
Xu L; Tang H; Wang K; Zheng Y; Feng J; Dong H; Jin Y; Cao C; Chen X; Gao G
Mol Med Rep; 2019 May; 19(5):4249-4255. PubMed ID: 30942459
[TBL] [Abstract][Full Text] [Related]
2. Blocking EZH2 methylation transferase activity by GSK126 decreases stem cell-like myeloma cells.
Zeng D; Liu M; Pan J
Oncotarget; 2017 Jan; 8(2):3396-3411. PubMed ID: 27926488
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic histone methyltransferase EZH2: A novel prognostic marker with therapeutic potential in endometrial cancer.
Oki S; Sone K; Oda K; Hamamoto R; Ikemura M; Maeda D; Takeuchi M; Tanikawa M; Mori-Uchino M; Nagasaka K; Miyasaka A; Kashiyama T; Ikeda Y; Arimoto T; Kuramoto H; Wada-Hiraike O; Kawana K; Fukayama M; Osuga Y; Fujii T
Oncotarget; 2017 Jun; 8(25):40402-40411. PubMed ID: 28418882
[TBL] [Abstract][Full Text] [Related]
4. Anti-cancer Effects of Curcumin on Myelodysplastic Syndrome through the Inhibition of Enhancer of Zeste Homolog-2 (EZH2).
Ma L; Zhang X; Wang Z; Huang L; Meng F; Hu L; Chen Y; Wei J
Curr Cancer Drug Targets; 2019; 19(9):729-741. PubMed ID: 30747066
[TBL] [Abstract][Full Text] [Related]
5. Identification of a chemical modulator of EZH2-mediated silencing by cell-based high-throughput screening assay.
Murashima A; Shinjo K; Katsushima K; Onuki T; Kondoh Y; Osada H; Kagaya N; Shin-Ya K; Kimura H; Yoshida M; Murakami S; Kondo Y
J Biochem; 2019 Jul; 166(1):41-50. PubMed ID: 30690451
[TBL] [Abstract][Full Text] [Related]
6. EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions.
Alzrigat M; Párraga AA; Agarwal P; Zureigat H; Österborg A; Nahi H; Ma A; Jin J; Nilsson K; Öberg F; Kalushkova A; Jernberg-Wiklund H
Oncotarget; 2017 Feb; 8(6):10213-10224. PubMed ID: 28052011
[TBL] [Abstract][Full Text] [Related]
7. Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic target.
Agarwal P; Alzrigat M; Párraga AA; Enroth S; Singh U; Ungerstedt J; Österborg A; Brown PJ; Ma A; Jin J; Nilsson K; Öberg F; Kalushkova A; Jernberg-Wiklund H
Oncotarget; 2016 Feb; 7(6):6809-23. PubMed ID: 26755663
[TBL] [Abstract][Full Text] [Related]
8. Effect and Mechanism of Curcumin on EZH2 - miR-101 Regulatory Feedback Loop in Multiple Myeloma.
Wu C; Ruan T; Liu W; Zhu X; Pan J; Lu W; Yan C; Tao K; Zhang W; Zhang C
Curr Pharm Des; 2018; 24(5):564-575. PubMed ID: 28322158
[TBL] [Abstract][Full Text] [Related]
9. Selective inhibition of EZH2 by ZLD1039 blocks H3K27 methylation and leads to potent anti-tumor activity in breast cancer.
Song X; Gao T; Wang N; Feng Q; You X; Ye T; Lei Q; Zhu Y; Xiong M; Xia Y; Yang F; Shi Y; Wei Y; Zhang L; Yu L
Sci Rep; 2016 Feb; 6():20864. PubMed ID: 26868841
[TBL] [Abstract][Full Text] [Related]
10. Knockdown of Enhancer of Zeste Homolog 2 Affects mRNA Expression of Genes Involved in the Induction of Resistance to Apoptosis in MOLT-4 Cells.
Naimi A; Safaei S; Entezari A; Solali S; Hassanzadeh A
Anticancer Agents Med Chem; 2020; 20(5):571-579. PubMed ID: 32000648
[TBL] [Abstract][Full Text] [Related]
11. A distinct metabolic response characterizes sensitivity to EZH2 inhibition in multiple myeloma.
Nylund P; Atienza Párraga A; Haglöf J; De Bruyne E; Menu E; Garrido-Zabala B; Ma A; Jin J; Öberg F; Vanderkerken K; Kalushkova A; Jernberg-Wiklund H
Cell Death Dis; 2021 Feb; 12(2):167. PubMed ID: 33579905
[TBL] [Abstract][Full Text] [Related]
12. Epigallocatechin gallate inhibits the proliferation and induces apoptosis of multiple myeloma cells via inactivating EZH2.
Zhou CG; Hui LM; Luo JM
Eur Rev Med Pharmacol Sci; 2018 Apr; 22(7):2093-2098. PubMed ID: 29687868
[TBL] [Abstract][Full Text] [Related]
13. Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.
Rizq O; Mimura N; Oshima M; Saraya A; Koide S; Kato Y; Aoyama K; Nakajima-Takagi Y; Wang C; Chiba T; Ma A; Jin J; Iseki T; Nakaseko C; Iwama A
Clin Cancer Res; 2017 Aug; 23(16):4817-4830. PubMed ID: 28490465
[No Abstract] [Full Text] [Related]
14. (-)-Epigallocatechin-3-gallate and EZH2 inhibitor GSK343 have similar inhibitory effects and mechanisms of action on colorectal cancer cells.
Ying L; Yan F; Williams BR; Xu P; Li X; Zhao Y; Hu Y; Wang Y; Xu D; Dai J
Clin Exp Pharmacol Physiol; 2018 Jan; 45(1):58-67. PubMed ID: 28925507
[TBL] [Abstract][Full Text] [Related]
15. MiRNA-26a Contributes to the Acquisition of Malignant Behaviors of Doctaxel-Resistant Lung Adenocarcinoma Cells through Targeting EZH2.
Chen J; Xu Y; Tao L; Pan Y; Zhang K; Wang R; Chen LB; Chu X
Cell Physiol Biochem; 2017; 41(2):583-597. PubMed ID: 28214878
[TBL] [Abstract][Full Text] [Related]
16. Small molecule epigenetic screen identifies novel EZH2 and HDAC inhibitors that target glioblastoma brain tumor-initiating cells.
Grinshtein N; Rioseco CC; Marcellus R; Uehling D; Aman A; Lun X; Muto O; Podmore L; Lever J; Shen Y; Blough MD; Cairncross GJ; Robbins SM; Jones SJ; Marra MA; Al-Awar R; Senger DL; Kaplan DR
Oncotarget; 2016 Sep; 7(37):59360-59376. PubMed ID: 27449082
[TBL] [Abstract][Full Text] [Related]
17. Identification of novel EZH2 inhibitors through pharmacophore-based virtual screening and biological assays.
Wu Y; Hu J; Ding H; Chen L; Zhang Y; Liu R; Xu P; Du D; Lu W; Liu J; Liu Y; Liu YC; Lu J; Zhang J; Yao Z; Luo C
Bioorg Med Chem Lett; 2016 Aug; 26(15):3813-7. PubMed ID: 27289323
[TBL] [Abstract][Full Text] [Related]
18. Targeting EZH2 as cancer therapy.
Hanaki S; Shimada M
J Biochem; 2021 Sep; 170(1):1-4. PubMed ID: 33479735
[TBL] [Abstract][Full Text] [Related]
19. EZH2 inhibition sensitizes tamoxifen‑resistant breast cancer cells through cell cycle regulation.
Chen S; Yao F; Xiao Q; Liu Q; Yang Y; Li X; Jiang G; Kuno T; Fang Y
Mol Med Rep; 2018 Feb; 17(2):2642-2650. PubMed ID: 29207119
[TBL] [Abstract][Full Text] [Related]
20. The Antitumoral Effect of the S-Adenosylhomocysteine Hydrolase Inhibitor, 3-Deazaneplanocin A, is Independent of EZH2 but is Correlated with EGFR Downregulation in Chondrosarcomas.
Aury-Landas J; Girard N; Lhuissier E; Adouane D; Delépée R; Boumediene K; Baugé C
Cell Physiol Biochem; 2019; 53(4):731-745. PubMed ID: 31613064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
